CIPLA / Q4-FY25 / claim-ledger

Audit the questions that mattered.

Cipla · Analyst questions, management answers, and the quality of the response where the ledger is available.

Research layer active

ConCallIQ research layer

Signal, with the source still visible.

Use the controls below to narrow the view, then follow the evidence into the next layer of context.

PositiveQ4-FY25 · 2025-04-30Back to quarter ↗

Questions audited

12

Answered directly

71%

Numeric claims

1

Consistency

contradicted

Question ledger

What was answered, and how?

Kunal Dhamesha · Macquarie

partial

Market positioning for Nano Paclitaxel launch in U.S.

Bulk of the market is, I think there are what we know, there is one NDA player, and there are two generics. I think one of the generics is any. We will continue to expand for ANDA generics because they are substitutable.

Kunal Dhamesha · Macquarie

partial

Total addressable market for Nano Paclitaxel

the market was $800 million-$900 million pre-generic. I think the IMS would still show it at that level, but there would be a gross to net to bring the market down

Kunal Dhamesha · Macquarie

direct

Advair launch timeline and regulatory status

Advair, as we mentioned, will be commercialized from our site in the U.S. ... we definitely see it as an FY 2026 launch. The question is, depending on the priority of the filing, we will probably either be launching it in the early part of the year or the later part of the year.

Kunal Dhamesha · Macquarie

partial

Impact of potential U.S. pharma tariffs

We have not in any way got impacted by any. This is an evolving situation. ... the most recent announcement does not really impact the generic players. In fact, it may just benefit.

Damayanti Kerai · HSBC

partial

Lanreotide supply normalization timeline

quarter four was significantly higher than quarter three. And in terms of volume, and also this quarter, we are coming back to normalcy. ... the product is quite significantly back into the channel.

Damayanti Kerai · HSBC

direct

R&D spending outlook and focus areas

we are really guiding to not being ever higher than 6%-6.5%, right? That is for a full year basis. ... Focus areas will continue to be respiratory, will continue to be injectables, will continue to be products in the products which are for India, including the GLP-1s

Surya Narayan Patra · PhillipCapital India Pvt Ltd

direct

Reason for lower margin guidance and Revlimid impact

generic Revlimid, which will go out of exclusivity towards the last quarter. That will certainly have an impact on overall margin. That's why we are guiding towards the margin number that we've given.

Surya Narayan Patra · PhillipCapital India Pvt Ltd

partial

CapEx for FY2026 and GLP-1 preparedness

About 4% roughly or 5% of your revenue, yeah, somewhere around that would be the figure for the CapEx, 5% of revenue you could take.

Neha Manpuria · Bank of America

partial

India market growth outlook and Cipla's performance

The overall market growth rate range of 10%-12% has now moved to 8%-10%. ... Cipla will do better than that overall in India.

Shashank Krishnakumar · Emkay Global

direct

Timeline for partnered inhalation asset commercialization

The asset is on track for commercialization. The asset was originally filed from Goa. It will be commercialized from Goa. We are also creating a new filing for, we are also supplementing the file if needed by also having the option of doing this from our U.S. facility.

Beno Parthi Parmar · Lara Capital

partial

Cipliqord launch timeline and Semaglutide update

27, yes. We should be hopefully there. ... I would rather not provide since the product is competitive.

Beno Parthi Parmar · Lara Capital

direct

U.S. run rate recovery with Lanreotide and Revlimid

If Lenalidomide might stay at where it was now, yes, we would have got there and crossed it. ... we are looking at something like $220 million for the U.S. going forward in the next quarter or so.